中国生物制品上市药品专利信息公示 | China Approved Biologics Patent Information - 聚焦大分子

最近更新 | Last Updated: 2024-03-25

抗体及抗体缀合物ANTIBODY & ANTIBODY CONJUGATE

PD-1抗体Anti-PD-1

纳武利尤单抗注射液 Nivolumab | 欧狄沃® OPDIVO®
- 上市许可持有人MAH: 百时美施贵宝Bristol-Myers Squibb
- 首批 (上市) First Approved (Launched): 2018-06-15 (2018-08-22)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200680023860.0 (保护期至Expiration 2026-05-02)
    - 专利权人Patent Owner: 小野薬品Ono Pharmaceutical; E. R. Squibb & Sons
    - 权利要求项Claim(s): 1-3, 11-13, 15-16
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201210554886.5 (保护期至Expiration 2026-05-02)
    - 专利权人Patent Owner: 小野薬品Ono Pharmaceutical; E. R. Squibb & Sons
    - 权利要求项Claim(s): 1-15, 28-30
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
帕博利珠单抗注射液 Pembrolizumab | 可瑞达® KEYTRUDA®
- 上市许可持有人MAH: 默沙东 Merck
- 首批 (上市) First Approved (Launched): 2018-07-26 (2018-09-25)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200880103544.3 (保护期至Expiration 2028-06-13)
    - 专利权人Patent Owner: 默沙东 Merck
    - 权利要求项Claim(s): 1-4, 13
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
信迪利单抗注射液 Sintilimab | 达伯舒® TYVYT®
- 上市许可持有人MAH: 信达生物Innovent Biologics
- 首批 (上市) First Approved (Launched): 2018-12-24 (2019-02-22)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201680040482.0 (保护期至Expiration 2036-08-09)
    - 专利权人Patent Owner: 信达生物Innovent Biologics
    - 权利要求项Claim(s): 1, 3, 5, 7, 9, 11, 16, 18, 23, 24, 27, 29, 30, 31
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: Z L 201910309687.X (保护期至Expiration 2036-08-09)
    - 专利权人Patent Owner: 信达生物Innovent Biologics
    - 权利要求项Claim(s): 1-13
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
卡瑞利珠单抗 Camrelizumab | 艾瑞卡® AIRUIKA™
- 上市许可持有人MAH: 苏州盛迪亚生物医药有限公司
- 首批 (上市) First Approved (Launched): 2019-05-29 (2019-07-22)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201480011008.6 (保护期至Expiration 2034-11-14)
    - 专利权人Patent Owner: 恒瑞医药Jiangsu Hengrui Medicine; 苏州盛迪亚生物医药有限公司
    - 权利要求项Claim(s): 1, 6-11, 21-26
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
替雷利珠单抗注射液 Tislelizumab | 百泽安®
- 上市许可持有人MAH: 百济神州BeiGene
- 首批 (上市) First Approved (Launched): 2019-12-26 (2020-03)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201380079581.6 (保护期至Expiration 2033-09-12)
    - 专利权人Patent Owner: 百济神州BeiGene
    - 权利要求项编号Claim(s): 3-7, 8-14
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201710207300.0 (保护期至Expiration 2033-09-12)
    - 专利权人Patent Owner: 百济神州BeiGene
    - 权利要求项编号Claim(s): 1, 2
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201710208535.1 (保护期至Expiration 2033-09-12)
    - 专利权人Patent Owner: 百济神州BeiGene
    - 权利要求项编号Claim(s): 1
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201810552595.X (保护期至Expiration 2033-09-12)
    - 专利权人Patent Owner: 百济神州BeiGene
    - 权利要求项编号Claim(s): 1
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL202011322081.9 (保护期至Expiration 2033-09-12)
    - 专利权人Patent Owner: 百济神州BeiGene
    - 权利要求项Claim(s): 1, 2
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
赛帕利单抗 Zimberelimab | 誉妥®
- 上市许可持有人MAH: 广州誉衡生物科技有限公司
- 首批 (上市) First Approved (Launched): 2021-08-25 (2021-10-16)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201610656318.4 (保护期至Expiration 2036-08-11)
    - 专利权人Patent Owner: 广州誉衡生物科技有限公司
    - 权利要求项编号Claim(s) No.: 1-19, 20-25
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
派安普利单抗 Penpulimab | 安尼可®
- 上市许可持有人MAH: 正大天晴Chia Tai-Tianqing
- 首批 (上市) First Approved (Launched): 2021-08-03 (2021-08-21)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201610705763.5 (保护期至Expiration 2036-08-23)
    - 专利权人Patent Owner: 正大天晴Chia Tai-Tianqing
    - 权利要求项编号Claim(s) No.: 1-34
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL202010761642.9 (保护期至Expiration 2040-07-31)
    - 专利权人Patent Owner: 正大天晴Chia Tai-Tianqing
    - 权利要求项Claim(s): 1-29, 40, 77-82
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
斯鲁利单抗 Serplulimab | 汉斯状® HANSIZHUANG®
- 上市许可持有人MAH: 复宏汉霖Henlius
- 首批 (上市) First Approved (Launched): 2022-03-22 (2022-04-02)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201780056868.5 (保护期至Expiration 2037-09-09)
    - 专利权人Patent Owner: 复宏汉霖Henlius
    - 权利要求项Claim(s): 1, 17-22
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use

PD-L1抗体Anti-PD-L1

度伐利尤单抗注射液 Durvalumab | 英飞凡® IMFINZI®
- 上市许可持有人MAH: 阿斯利康AstraZeneca
- 首批 (上市) First Approved (Launched): 2019-12-06 (2020-02-14)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201080053042.1 (保护期至Expiration 2030-11-24)
    - 专利权人Patent Owner: 米迪缪尼MedImmune
    - 权利要求项Claim(s): 1-4, 6-8, 10-12
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
阿替利珠单抗注射液 Atezolizumab | 泰圣奇® TECENTRIQ ®
- 上市许可持有人MAH: 罗氏Roche
- 首批 (上市) First Approved (Launched): 2020-02-13 (2020-04-29)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200980149532.9 (保护期至Expiration 2029-12-08)
    - 专利权人Patent Owner: 罗氏Roche
    - 权利要求项Claim(s): 1-8, 19, 40, 43, 53
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201410743500.4 (保护期至Expiration 2029-12-08)
    - 专利权人Patent Owner: 罗氏Roche
    - 权利要求项Claim(s): 1-13, 15, 34-40
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201480064099.X (保护期至Expiration 2034-09-26)
    - 专利权人Patent Owner: 罗氏Roche
    - 权利要求项Claim(s): 36
    - 专利类型Patent Type: 医药用途Medical use
舒格利单抗 Sugemalimab | 择捷美® CEJEMLY®
- 上市许可持有人MAH: 辉瑞Pfizer
- 首批 (上市) First Approved (Launched): 2021-12-20 (2021-01-14)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201610638134.5 (保护期至Expiration 2036-08-05)
    - 专利权人Patent Owner: 基石药业CStone Pharmaceuticals; 拓石药业
    - 权利要求项Claim(s): 1-12, 14, 25-27
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
恩沃利单抗 Envafolimab | 恩维达® ENWEIDA®
- 上市许可持有人MAH: 四川思路康瑞药业
- 首批 (上市) First Approved (Launched): 2021-11-24 (2021-12-06)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201680031072 .X (保护期至Expiration 2036-08-01)
    - 专利权人Patent Owner: 康宁杰瑞Alphamab Oncology; 思路迪医药3D Medicines
    - 权利要求项Claim(s): 1-11, 17-22
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
阿得贝利单抗 Adebrelimab | 艾瑞利®
- 上市许可持有人MAH: 上海盛迪医药Shanghai Shengdi Medicine
- 首批 (上市) First Approved (Launched): 2023-02-28 (2023-03-06)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201680027181.4 (保护期至Expiration 2036-11-02)
    - 专利权人Patent Owner: 上海盛迪医药Shanghai Shengdi Medicine; 苏州盛迪亚生物医药有限公司; 恒瑞医药Jiangsu Hengrui Medicine
    - 权利要求项Claim(s): 1-8, 11-12, 14, 16-18, 23-26
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use

PCSK9抗体Anti-PCSK9

依洛尤单抗 Evolocumab | 瑞百安® REPATHA®
- 上市许可持有人MAH: 安进Amgen
- 首批 (上市) First Approved (Launched): 2018-07-31 (2019-03-23)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201380035382.5 (保护期至Expiration 2033-05-02)
    - 专利权人Patent Owner: 安进Amgen
    - 权利要求项Claim(s): 17-20
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL200880113475.4 (保护期至Expiration 2028-08-21)
    - 专利权人Patent Owner: 安进 Amgen
    - 权利要求项Claim(s): 1-7, 9-14, 16-17, 25-29
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201280034417.9 (保护期至Expiration 2023-05-09)
    - 专利权人Patent Owner: 安进Amgen
    - 权利要求项Claim(s): 2-23, 27, 33-35, 37, 39, 40, 42, 43, 47-52, 54-58, 60
    - 专利类型Patent Type: 医药用途Medical Use
阿利西尤单抗 Alirocumab | 波立达® PRALUENT®
- 上市许可持有人MAH: 赛诺菲Sanofi
- 首批 (上市) First Approved (Launched): 2019-12-26 (2020-04-19)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200980150206.X (保护期至Expiration 2029-12-15)
    - 专利权人Patent Owner: 再生元制药Regeneron
    - 权利要求项Claim(s): 1-2, 8-9
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201280044795.5 (保护期至Expiration 2032-09-12)
    - 专利权人Patent Owner: 再生元制药Regeneron
    - 权利要求项Claim(s) No.: 1-8, 11-12, 15-23
    - 专利类型Patent Type: 医药用途Medical Use

HER2抗体及缀合物Anti-HER2

帕妥珠单抗注射液 Pertuzumab | 帕捷特® PERJETA®
- 上市许可持有人MAH: 罗氏Roche
- 首批 (上市) First Approved (Launched): 2018-12-17 (2019-04)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201210006776.5 (保护期至Expiration 2025-06-15)
    - 专利权人Patent Owner: 罗氏Roche
    - 权利要求项Claim(s): 1-6, 8-11, 13, 15, 19-27
    - 专利类型Patent Type: 医药用途Medical use
  - 专利号Patent No.: ZL200680013738.5 (保护期至Expiration 2026-02-21)
    - 专利权人Patent Owner: 罗氏Roche
    - 权利要求项Claim(s): 1-2, 5-14
    - 专利类型Patent Type: 医药用途Medical use
  - 专利号Patent No.: ZL200980111007.8 (保护期至Expiration 2029-01-28)
    - 专利权人Patent Owner: 罗氏Roche
    - 权利要求项Claim(s): 9, 10
    - 专利类型Patent Type:医药用途Medical use
  - 专利号Patent No.: ZL200580031905.4 (保护期至Expiration 2025-07-15)
    - 专利权人Patent Owner: 罗氏Roche
    - 权利要求项Claim(s): 12, 13
    - 专利类型Patent Type: 医药用途Medical use
恩美曲妥珠单抗Ado-Trastuzumab Emtansine | 赫赛莱® KADCYLA® (抗体偶联药物ADC)
- 上市许可持有人MAH: 罗氏Roche
- 首批 (上市) First Approved (Launched): 2020-01-21 (2020-04)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201810464381.7 (保护期至Expiration 2024-10-12)
    - 专利权人Patent Owner: 伊缪诺金Immunogen
    - 权利要求项Claim(s): 1-2
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
维迪西妥单抗 Disitamab | 爱地希® AIDIXI®
- 上市许可持有人MAH: 荣昌生物RemeGen
- 首批 (上市) First Approved (Launched): 2021-06-08 (2021-07-02)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201480006648.8 (保护期至Expiration 2034-11-18)
    - 专利权人Patent Owner: 荣昌生物RemeGen
    - 权利要求项Claim(s): 1, 14
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
德曲妥珠单抗 Trastuzumab Deruxtecan | 优赫得® ENHERTU® (抗体偶联药物ADC)
- 上市许可持有人MAH: 第一三共Daiichi Sankyo
- 首批 (上市) First Approved (Launched): 2023-02-24 (2023-06-21)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201380053256.2 (保护期至Expiration 2033-10-10)
    - 专利权人Patent Owner: 第一三共Daiichi Sankyo
    - 权利要求项Claim(s): 1-20
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL201580003121.4 (保护期至Expiration 2035-1-28)
    - 专利权人Patent Owner: 第一三共Daiichi Sankyo
    - 权利要求项编Claim(s): 1-16
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence

CD19抗体Anti-CD19

伊奈利珠单抗注射液 Inebilizumab | 昕越® UPLIZNA®
- 上市许可持有人MAH: 地平线治疗Horizon Therapeutics
- 首批 (上市) First Approved (Launched): 2022-03-08 (未上市Not Yet Launched)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200780033355.9 (保护期至Expiration 2027-09-07)
    - 专利权人Patent Owner: 米迪缪尼MedImmune
    - 权利要求项Claim(s): 1-6, 9-14, 17-41
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use

CD20抗体Anti-CD20

奥妥珠单抗注射液 Obinutuzumab | 佳罗华® GAZYVA®
- 上市许可持有人MAH: 罗氏Roche
- 首批 (上市) First Approved (Launched): 2021-06-01 (2021-08-27)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200480039946.3 (保护期至Expiration 2024-11-05)
    - 专利权人Patent Owner: 罗氏Roche
    - 权利要求项Claim(s): 1-14, 24-26
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
奥法妥木单抗Ofatumumab | 全欣达^® KESIMPTA^®
- 上市许可持有人MAH: 诺华Novartis
- 首批 (上市) First Approved (Launched): 2021-12-20 (2022-03-24)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201310412401.3 (保护期至Expiration 2023-10-17)
    - 专利权人Patent Owner: 根马布Genmab
    - 权利要求项Claim(s): 3
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL200380106690.9 (保护期至Expiration 2023-10-17)
    - 专利权人Patent Owner: 根马布Genmab
    - 权利要求项编号Claim(s): 1-5, 22-25, 37-38
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL200880105866.1 (保护期至Expiration 2028-07-03)
    - 专利权人Patent Owner: 诺华 Novartis
    - 权利要求项Claim(s): 18-21, 24
    - 专利类型Patent Type: 医药用途Medical Use

CD38抗体Anti-CD38

达雷妥尤单抗 Daratumumab | 兆珂® DARZALEX®
- 上市许可持有人MAH: 詹森Janssen-Cilag
- 首批 (上市) First Approved (Launched): 2019-07-04 (2019-10-15)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200680017915.7 (保护期至Expiration 2026-03-22)
    - 专利权人Patent Owner: 根马布Genmab
    - 权利要求项Claim(s): 1-4, 6, 8-10, 13, 29, 30, 34-36, 40, 41
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201710164800.0 (保护期至Expiration 2026-03-22)
    - 专利权人Patent Owner: 根马布Genmab
    - 权利要求项Claim(s): 19, 20, 22, 25-27, 29, 30
    - 专利类型Patent Type: 医药用途Medical use

CD79B抗体Anti-CD79B

注射用维泊妥珠单抗 Polatuzumab Vedotin | 优罗华® POLIVY®
- 上市许可持有人MAH: 罗氏Roche
- 首批 (上市) First Approved (Launched): 2023-01-10 (2023-03-19)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200880107332.2 (保护期至Expiration 2028-07-15)
    - 专利权人Patent Owner: 健泰科Genentech
    - 权利要求项Claim(s): 1-3, 7-8, 10, 13, 21-26, 37-38, 41-42, 44, 52-57, 60-63, 65-66, 67-72, 116-118; 78, 80-84, 88, 90-94
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201410106447.7 (保护期至Expiration 2028-07-15)
    - 专利权人Patent Owner: 健泰科Genentech
    - 权利要求项Claim(s): 1-3, 6-9; 11, 13-17, 19-22
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201610853255.1 (保护期至Expiration 2028-07-15)
    - 专利权人Patent Owner: 健泰科Genentech
    - 权利要求项Claim(s): 7, 14-15, 28-33, 35-36, 38-39, 42-45, 46-51, 53, 56-58, 59-64, 66, 69-71; 77-81, 83-87, 89-98, 101-105, 107-109, 113-114
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use

白介素受体抗体 Anti-Interleukin Receptor

IL-4R: 度普利尤单抗 Dupilumab | 达必妥® DUPIXENT®
- 上市许可持有人MAH: 赛诺菲Sanofi
- 首批 (上市) First Approved (Launched): 2020-06-17 (2020-07-22)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200980143007.6 (保护期至Expiration 2029-10-27)
    - 专利权人Patent Owner: 再生元制药 Regeneron
    - 权利要求项Claim(s): 1-5, 13, 16
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201410018529.6 (保护期至Expiration 2029-10-27)
    - 专利权人Patent Owner: 再生元制药 Regeneron
    - 权利要求项Claim(s): 1-8, 16
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
IL-6R: 托珠单抗Tocilizumab | 雅美罗® ACTEMRA®
- 上市许可持有人MAH: 罗氏Roche
- 首批 (上市) First Approved (Launched): 2013-03-26 (2013)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200480011401.1 (保护期至Expiration 2024-04-28 )
    - 专利权人Patent Owner: 中外制药Chugai
    - 权利要求项编号Claim(s): 10-18
    - 专利类型Patent Type: 医药用Medical Use
  - 专利号Patent No.: ZL202010040597.8 (保护期至Expiration 2024-04-28)
    - 专利权人Patent Owner: 中外制药Chugai
    - 权利要求项编号Claim(s): 1-11
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL201511004468.9 (保护期至Expiration 2024-04-28)
    - 专利权人Patent Owner: 中外制药Chugai
    - 权利要求项Claim(s): 7-12
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL02807784.9 (保护期至Expiration 2022-04-02)
    - 专利权人Patent Owner: 中外制药Chugai
    - 权利要求项Claim(s): 1-4, 6-7, 9-21, 23-24, 26-27, 29
    - 专利类型Patent Type: 医药用途Medical Use
IL-6R: 萨特利珠单抗Satralizumab | 安适平® ENSPRYNG®
- 上市许可持有人MAH: 罗氏Roche
- 首批 (上市) First Approved (Launched): 2021-04-30 (未上市Not Yet Launched)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200980100709.6 (保护期至Expiration 2029-09-25)
    - 专利权人Patent Owner: 中外制药Chugai
    - 权利要求项Claim(s): 1-3
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
IL-12R: 乌司奴单抗Ustekinumab | 喜达诺®, STELARA®
- 上市许可持有人MAH: 詹森Janssen-Cilag
- 首批 (上市) First Approved (Launched): 2017-11-07 (2019-05-20)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200810100025.3 (保护期至Expiration 2021-08-06)
    - 专利权人Patent Owner: 森托科尔Centocor
    - 权利要求项Claim(s): 1-6, 8-13
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
IL-17R: 依奇珠单抗 Ixekizumab | 拓咨® TALTZ®
- 上市许可持有人MAH: 礼来Eli Lilly
- 首批 (上市) First Approved (Launched): 2019-08-29 (2019)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200680046605.8 (保护期至Expiration 2026-12-05)
    - 专利权人Patent Owner: 礼来Eli Lilly
    - 权利要求项Claim(s): 1-7
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201380012452.5 (保护期至Expiration 2033-03-01)
    - 专利权人Patent Owner: 礼来Eli Lilly
    - 权利要求项Claim(s): 1-10
    - 专利类型Patent Type: 医药用途Medical Use
IL-23R: 古塞奇尤单抗 Guselkumab | 特诺雅® TREMFYA®
- 上市许可持有人MAH: 詹森Janssen-Cilag
- 首批 (上市) First Approved (Launched): 2019-12-26 (2020-04-21)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200680053546.7 (保护期至Expiration 2026-12-27)
    - 专利权人Patent Owner: 森托科尔Centocor
    - 权利要求项Claim(s): 2, 4-8, 21-25
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL201210297501.1 (保护期至Expiration 2026-12-27)
    - 专利权人Patent Owner: 詹森生物科技 Janssen Biotech
    - 权利要求项Claim(s): 1-5
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
IL-36R: 佩索利单抗 Spesolimab | 圣利卓® SPEVIGO®
- 上市许可持有人MAH: 勃林格殷格翰Boehringer Ingelheim
- 首批 (上市) First Approved (Launched): 2020-12-13 (2023-05-14)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: 201280054425.X (保护期至Expiration 2032-11-14)
    - 专利权人Patent Owner: 勃林格殷格翰Boehringer Ingelheim
    - 权利要求项Claim(s): 1, 3, 11, 20, 29-31, 44
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: 201610916419.0 (保护期至Expiration 2032-11-14)
    - 专利权人Patent Owner: 勃林格殷格翰Boehringer Ingelheim
    - 权利要求项Claim(s): 1, 3, 11, 20
    - 专利类型Patent Type: 医药用途Medical Use

白细胞介素抗体 Anti-Interleukin

IL-6: 司妥昔单抗Siltuximab | 萨温珂® SYLVANT®
- 上市许可持有人MAH: EUSA Pharma
- 首批 (上市) First Approved (Launched): 2021-11-30 (2022-07-24)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL02829803.9 (保护期至Expiration 2022-10-25)
    - 专利权人Patent Owner: EUSA Pharma
    - 权利要求项Claim(s): 1-10, 23, 31, 33
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
IL-17A: 司库奇尤单抗注射液 Secukinumab | 可善挺® COSENTYX®
- 上市许可持有人MAH: 诺华Novartis
- 首批 (上市) First Approved (Launched): 2019-03-28 (2019-03)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200580026569.4 (保护期至Expiration 2025-08-04)
    - 专利权人Patent Owner: 诺华Novartis
    - 权利要求项Claim(s) No.: 1-5
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL202111452382.8 (保护期至Expiration 2035-12-21)
    - 专利权人Patent Owner: 诺华Novartis
    - 权利要求项Claim(s): 1-28
    - 专利类型Patent Type: 医药用途Medical Use

其他单特异性抗体Other Monospecific Antibodies

肿瘤坏死因子–α (TNF-α): 戈利木单抗 Golimumab | 欣普尼® SIMPONI®
- 上市许可持有人MAH: 詹森生物Janssen Biotech
- 首批 (上市) First Approved (Launched): 2018-01-04 (2018-06-20)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL01816960.0 (保护期至Expiration 2021-08-06)
    - 专利权人Patent Owner: 詹森生物Janssen Biologics
    - 权利要求项Claim(s): 1-3, 10-12
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL201010156291.5 (保护期至Expiration 2021-08-06)
    - 专利权人Patent Owner: 詹森生物Janssen Biotech
    - 权利要求项Claim(s): 1-8
    - 专利类型Patent Type: 医药用途Medical use
达比加群 (Dabigatran): 依达赛珠单抗 Idarucizumab | 泰毕安®, PRAXBIND®
- 上市许可持有人MAH: 宝灵家殷格翰Boehringer Ingelheim
- 首批 (上市) First Approved (Launched): 2018-06-08 (2019-03-09)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201180006616.4 (保护期至Expiration 2031-01-20)
    - 专利权人Patent Owner: 宝灵家殷格翰 Boehringer Ingelheim
    - 权利要求项Claim(s): 1, 2-3, 9
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
补体成分5 (Complement Component 5, C5): 依库珠单抗 Eculizumab | 舒立瑞^® SOLIRIS^®
- 上市许可持有人MAH: 瑞颂Alexion
- 首批 (上市) First Approved (Launched): 2018-09-04 (2022-11-11)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200980153390.3 (保护期至Expiration 2029-11-10)
    - 专利权人Patent Owner: 瑞颂Alexion
    - 权利要求项Claim(s): 1, 7-22
    - 专利类型Patent Type: 医药用途Medical use
核因子-κB受体活化因子(RANKL): 地舒单抗注射液 Denosumab | 安加维® XGEVA®
- 上市许可持有人MAH: 安进Amgen
- 首批 (上市) First Approved (Launched): 2019-05-21 (2020-07-01)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201310052370.5 (保护期至Expiration 2022-06-24)
    - 专利权人Patent Owner: 安进Amgen
    - 权利要求项Claim(s): 1-25, 27-32
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
整合素α4β7 (α4β7 Integrin): 维得利珠单抗 Vedolizumab | 安吉优^® ENTYVIO^®
- 上市许可持有人MAH: 武田Takeda
- 首批 (上市) First Approved (Launched): 2020-03-11 (2021-11-22)
- 专利信息登记详情Registered Patent (s)
  - 专利号Patent No.: ZL201711310404.0 (保护期至Expiration 2032-05-02)
    - 专利权人Patent Owner: 千禧制药Millennium Pharmaceuticals
    - 权利要求项Claim(s): 1-10
    - 专利类型Patent Type: 医药用途Medical Use
血浆前激肽释放酶 (Plasma Kallikrein): 拉那利尤单抗 Lanadelumab | 达泽优® AKHZYRO®
- 上市许可持有人MAH: 武田Takeda
- 首批 (上市) First Approved (Launched): 2020-12-02 (2021-05)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201280011286.2 (保护期至Expiration 2032-01-05)
    - 专利权人Patent Owner: 武田Takeda
    - 权利要求项Claim(s): 1-3, 5, 6, 9
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201610164388.8 (保护期至Expiration 2032-01-05)
    - 专利权人Patent Owner: 武田 Takeda
    - 权利要求项Claim(s): 1-3
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
成纤维细胞生长因子23 (FGF23): 布罗索尤单抗 Burosumab | 麟平® CRYSVITA®
- 上市许可持有人MAH: 协和麒麟Kyowa Kirin
- 首批 (上市) First Approved (Launched): 2021-01-05 (2021-07-31)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200880004814.5 (保护期至Expiration 2028-02-14)
    - 专利权人Patent Owner: 协和麒麟Kyowa Kirin
    - 权利要求项Claim(s): 1-8, 9-12, 13-16
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201210161119.8 (保护期至Expiration 2028-02-14)
    - 专利权人Patent Owner: 协和麒麟Kyowa Kirin
    - 权利要求项Claim(s): 1-7
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
滋养层细胞表面抗原2 (Trop-2): 戈沙妥珠单抗 Sacituzumab Govitecan | 拓达维®Trodelvy® (抗体偶联药物ADC)
- 上市许可持有人MAH: 吉利德Gilead
- 首批 (上市) First Approved (Launched): 2022-06-07 (未上市Not Yet Launched)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL03809918.7 (保护期至Expiration 2023-03-03)
    - 专利权人Patent Owner: 免疫医疗公司Immunomedics
    - 权利要求项Claim(s): 1-8, 19-23, 38-42, 48, 62-66, 68-78, 80-81, 96
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL200710185161.2 (保护期至Expiration 2023-03-03)
    - 专利权人Patent Owner: 免疫医疗公司Immunomedics
    - 权利要求项Claim(s): 1, 2, 9-23
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL200980156218.3 (保护期至Expiration 2029-12-02)
    - 专利权人Patent Owner: 免疫医疗公司Immunomedics
    - 权利要求项Claim(s): 1-4, 7-9, 13-14, 17-22, 26-30
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201680036918.9 (保护期至Expiration 2036-06-23)
    - 专利权人Patent Owner: 免疫医疗公司Immunomedics
    - 权利要求项Claim(s): 1, 3-7, 12, 16-21
    - 专利类型Patent Type: 医药用途Medical Use
双唾液酸神经节苷脂GD2: 那西妥单抗注射液Naxitamab-Gqgk | DANYELZA® 达佑泽® (与粒细胞-巨噬细胞集落刺激因子联合给药Combination with GM-CSF)
- 上市许可持有人MAH: Y-mAbs
- 首批 (上市) First Approved (Launched): 2022-11-30 (2023-07-01)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201180040144.4 (保护期至Expiration 2031-06-20)
    - 专利权人Patent Owner: 纪念斯隆-凯特琳癌症中心 Memorial Sloan Kettering
    - 权利要求项Claim(s): 1, 3, 15, 16
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use

双/多特异性抗体Bispecific/Multi-Specific Antibodies

凝血因子IXa×凝血因子X (Factor Xa×Factor X): 艾美赛珠单抗 Emicizumab | 舒友立乐® HEMLIBRA®
- 上市许可持有人MAH: 罗氏 Roche
- 首批 (上市) First Approved (Launched): 2018-11-30 (2019-05)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201180065133.1 (保护期至Expiration 2031-11-17)
    - 专利权人Patent Owner: 中外制药Chugai
    - 权利要求项Claim(s): 1, 13
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201610299812.X (保护期至Expiration 2031-11-17)
    - 专利权人Patent Owner: 中外制药 Chugai
    - 权利要求项Claim(s): 1, 9-12
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
CD19×CD3: 贝林妥欧单抗Blinatumomab | 倍利妥® BLINCYTO® (T 细胞衔接器BiTE)
- 上市许可持有人MAH: 安进Amgen
- 首批 (上市) First Approved (Launched): 2020-12-02 (2021-08-19)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200980144400.7 (保护期至Expiration 2029-11-05)
    - 专利权人Patent Owner: 安进Amgen
    - 权利要求项Claim(s): 1-4, 11, 12, 17和18
    - 专利类型Patent Type: 医药用途Medical Use
PD-1×CTLA-4: 卡度尼利单抗Cadonilimab | 开坦尼^®
- 上市许可持有人MAH: 康方生物Akeso
- 首批 (上市) First Approved (Launched): 2022-06-28 (2022-07-09)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201610705624.2 (保护期至Expiration 2036-08-23)
    - 专利权人Patent Owner: 康方生物Akeso
    - 权利要求项Claim(s): 1-31
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence

酶、重组蛋白、融合蛋白ENZYME, RECOMBINANT PROTEIN & FUSION PROTEIN

粒细胞集落刺激因子 (G-CSF)

硫培非格司亭 Mecapegfilgrastim | 艾多® (聚乙二醇修饰Pegylated)
- 上市许可持有人MAH: 恒瑞医药Jiangsu Hengrui Medicine
- 首批 (上市) First Approved (Launched): 2018-05-08 (2018-07-15)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200610142737.2 (保护期至Expiration 2026-10-30)
    - 专利权人Patent Owner: 恒瑞医药Jiangsu Hengrui Medicine
    - 权利要求项Claim(s): 1-4, 6, 10, 12
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
艾贝格司亭α Efbemalenograstim Alfa | 亿立舒® RYZNEUTA® (双分子Fc融合蛋白Dimeric Fc Fusion)
- 上市许可持有人MAH: 亿一生物Evive Biotech
- 首批 (上市) First Approved (Launched): 2023-05-06 (2023-06-21)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201510112334.2 (保护期至Expiration 2031-05-25)
    - 专利权人Patent Owner: 亿一生物Evive Biotech
    - 权利要求项Claim(s): 1-7
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201180041735.3 (保护期至Expiration 2031-08-31)
    - 专利权人Patent Owner: 亿一生物Evive Biotech
    - 权利要求项Claim(s): 1-4, 6-7, 9
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use

激活素受体2B (ACVR2B)

罗特西普 Luspatercept | 利布洛泽® REBLOZYL® (Fc融合蛋白Fc Fusion)
- 上市许可持有人MAH: 赛尔基因Celgene Corporation
- 首批 (上市) First Approved (Launched): 2022-01-25 (2022-06-14)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200880011247.6 (保护期至Expiration 2028-02-04)
    - 专利权人Patent Owner: 阿塞勒隆Acceleron
    - 权利要求项Claim(s): 1, 3, 5, 7-12
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL201510979350.1 (保护期至Expiration 2030-08-13)
    - 专利权人Patent Owner: 阿塞勒隆Acceleron
    - 权利要求项Claim(s): 1-2, 21
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL201280061672.2 (保护期至Expiration 2032-10-17)
    - 专利权人Patent Owner: 阿塞勒隆Acceleron
    - 权利要求项Claim(s): 1-16, 18-21, 25-36
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL201610236454.8 (保护期至Expiration 2028-02-04)
    - 专利权人Patent Owner: 阿塞勒隆Acceleron
    - 权利要求项Claim(s): 1, 2, 4, 6, 8-15
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL201580043170.0 (保护期至Expiration 2035-06-12)
    - 专利权人Patent Owner: 阿塞勒隆Acceleron
    - 权利要求项Claim(s): 1-3, 5-14, 19-24, 26-31
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL201510979490.9 (保护期至Expiration 2030-08-13)
    - 专利权人Patent Owner: 阿塞勒隆Acceleron
    - 权利要求项Claim(s): 1-2, 4-5, 8-9
    - 专利类型Patent Type: 医药用途Medical Use

跨膜激活剂及钙调亲环素配基相互作用因子 (TACI)

泰它西普 Telitacicept | 泰爱® TAI’AI® (Fc融合蛋白Fc Fusion)
- 上市许可持有人MAH: 荣昌生物RemeGen
- 首批 (上市) First Approved (Launched): 2021-03-09 (2021-04)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200710111162.2 (保护期至Expiration 2027-06-15)
    - 专利权人Patent Owner: 荣昌生物RemeGen
    - 权利要求项Claim(s): 1, 9
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence

血管内皮生长因子受体 (VEGF Receptor)

康柏西普 Conbercept | 朗沐® LUMITIN® (Fc融合的VEGFR1/VEGFR2嵌合蛋白 Chimeric VEGFR1/VEGFR2 Fc Fusion)
- 上市许可持有人MAH: 康弘药业Kanghong
- 首批 (上市) First Approved (Launched): 2013-11-27 (2014-05)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200510073595.4 (保护期至Expiration 2025-06-06)
    - 专利权人Patent Owner: 康弘药业Kanghong
    - 权利要求项Claim(s): 1, 5
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL200610066257.2 (保护期至Expiration 2026-03-31)
    - 专利权人Patent Owner: 康弘药业Kanghong
    - 权利要求项Claim(s): 1, 4-9
    - 专利类型Patent Type: 医药用途Medical Use

胰高血糖素样肽-1及类似物 (GLP-1 and Analogues)

度拉糖肽Dulaglutide | 度易达® TRULICITY® (Fc融合蛋白Fc Fusion)
- 上市许可持有人MAH: 礼来Eli Lilly
- 首批 (上市) First Approved (Launched): 2019-02-22 (2019-06-16)
- 信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200480015953.X (保护期至Expiration 2024-06-10)
    - 专利权人Patent Owner: 礼来 Eli Lilly
    - 权利要求项Claim(s): 1-4, 6-7, 9, 10
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL201010508567.1 (保护期至Expiration 2024-06-10)
    - 专利权人Patent Owner: 礼来 Eli Lilly
    - 权利要求项Claim(s): 1, 2
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL200580035597.2 (保护期至Expiration 2025-12-15)
    - 专利权人Patent Owner: 礼来 Eli Lilly
    - 权利要求项Claim(s): 1-4, 8
    - 专利类型Patent Type: 医药用途Medical Use
司美格鲁肽 Semaglutide | 诺和泰® OZEMPIC® (类似物 Analogue)
- 上市许可持有人MAH: 诺和诺德Novo Nordisk
- 首批 (上市) First Approved (Launched): 2021-04-27 (2021-08-14)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200680006674.6 (保护期至Expiration 2026-03-20)
    - 专利权人Patent Owner: 诺和诺德公 Novo Nordisk
    - 权利要求项Claim(s) No.: 1, 3, 4
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
  - 专利号Patent No.: ZL 201780026303.2 (保护期至Expiration 2037-04-28)
    - 专利权人Patent Owner: 诺和诺德Novo Nordisk
    - 权利要求项Claim(s): 1-8, 10-16, 18-29
    - 专利类型Patent Type: 医药用途Medical Use

神经生长因子 (Nerve Growth Factor, NGF)

塞奈吉明 Cenegermin | 欧适维® OXERVATE®
- 上市许可持有人MAH: 东沛制药Dompé farmaceutici S.p.A.
- 首批 (上市) First Approved (Launched): 2020-08-12 (2022-03停止推广Marketing Stopped)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201280062855.6 (保护期至Expiration 2032-12-18)
    - 专利权人Patent Owner: 瓦克Wacker
    - 权利要求项Claim(s): 1-3, 4-27
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use

胰岛素及衍生物 (Insulin and Derivatives)

甘精胰岛素Insulin Glargine | 来得时 ® LANTUS®
- 上市许可持有人MAH: 赛诺菲Sanofi
- 首批 (上市) First Approved (Launched): 2003-11-07 (2004)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201480020095.1 (保护期至Expiration 2034-04-01)
    - 专利权人Patent Owner: 赛诺菲Sanofi
    - 权利要求项Claim(s) No.: 1-15, 17-18, 20-32
    - 专利类型Patent Type: 医药用途Medical Use
德谷胰岛素Insulin Degludec | 诺和达® TRESIBA®
- 上市许可持有人MAH: 诺和诺德Novo Nordisk
- 首批 (上市) First Approved (Launched): 2017-09-20 (2018-03-10)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL 200680053516.6 (保护期至Expiration 2026-12-21)
    - 专利权人Patent Owner: 诺和诺德Novo Nordisk
    - 权利要求项Claim(s): 2, 4, 6
    - 专利类型Patent Type: 医药用途Medical Use
德谷门冬双胰岛素Insulin Degludec and Insulin Aspart | 诺和佳® RYZODEG®
- 上市许可持有人MAH: 诺和诺德Novo Nordisk
- 首批 (上市) First Approved (Launched): 2019-05-21 (2019-12-07)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200480021733.8 (保护期至Expiration 2024-07-22)
    - 专利权人Patent Owner: 诺和诺德Novo Nordisk
    - 权利要求项Claim(s): 1-4, 8-10
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
德谷胰岛素利拉鲁肽Insulin Degludec and Liraglutide | 诺和益® XULTOPHY®
- 上市许可持有人MAH: 诺和诺德Novo Nordisk
- 首批 (上市) First Approved (Launched): 2021-10-26 (2022-03-05)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200480021733.8 (保护期至Expiration 2024-07-22)
    - 专利权人Patent Owner: 诺和诺德Novo Nordisk
    - 权利要求项Claim(s): 1-4, 8-10
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence; 医药用途Medical Use
甘精胰岛素利司那肽 (I)、(II) Insulin Glargine and Lixisenatide Injection (I), (II) | 赛益宁® SOLIQUA®
- 上市许可持有人MAH: 赛诺菲Sanofi
- 首批 (上市) First Approved (Launched): 2023-01-10 (2023-05-22)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent: ZL201080061410.7 (保护期至Expiration 2030-11-11)
    - 专利权人Patent Owner: 赛诺菲Sanofi
    - 权利要求项Claim(s): 15-16, 18-23
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent: ZL201710447024.5 (保护期至Expiration 2030-11-11)
    - 专利权人Patent Owner: 赛诺菲Sanofi
    - 权利要求项Claim(s) No.: 7-18
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent: ZL201480045284.4 (保护期至Expiration 2034-06-13)
    - 专利权人Patent Owner: 赛诺菲Sanofi
    - 权利要求项Claim(s): 10-21
    - 专利类型Patent Type: 医药用途Medical Use

干扰素 (Interferon, IFN)

IFN-α1b: 人干扰素α1b Human IFN-α1b | 运德素®
- 上市许可持有人MAH: 三元基因Tri-Prime Gene
- 首批 (上市) First Approved (Launched): 1999 (2000)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200410069390.4 (保护期至Expiration 2024-07-22)
    - 专利权人Patent Owner: 三元基因Tri-Prime Gene
    - 权利要求项Claim(s): 1-3
    - 专利类型Patent Type: 医药用途Medical Use
IFN-α2: 培集成干扰素α-2注射液Peginterferon alfacon-2 | 派益生® (聚乙二醇修饰Pegylated)
- 上市许可持有人MAH: 凯因科技Kawin
- 首批 (上市) First Approved (Launched): 2018-06-28 (未上市Not Yet Launched)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201410146151.8 (保护期至Expiration 2030-10-25)
    - 专利权人Patent Owner: 凯因科技Kawin
    - 权利要求项Claim(s): 10
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence

酶Enzyme

艾度硫酸酯酶β Idursulfase β | 海芮思® HUNTERASE®
- 上市许可持有人MAH: 绿十字GC Biopharma
- 首批 (上市) First Approved (Launched): 2020-09-02 (2021-05)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201280030629.X (保护期至Expiration 2032-06-15)
    - 专利权人Patent Owner: 绿十字GC Biopharma
    - 权利要求项Claim(s): 1-14
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
维拉苷酶αVelaglucerase alfa | 维葡瑞 ® VPRIV®
- 上市许可持有人MAH: 武田Takeda
- 首批 (上市) First Approved (Launched): 2021-04-27 (2022-02-26)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201510580649.X (保护期至Expiration 2030-07-27)
    - 专利权人Patent Owner: 武田Takeda
    - 权利要求项Claim(s): 27
    - 专利类型Patent Type: 医药用途Medical Use

疫苗 VACCINE

肺炎球菌疫苗Pneumococcal Vaccine

13价肺炎球菌多糖结合疫苗13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) | 沛儿® PREVENAR 13®
- 上市许可持有人MAH: 辉瑞Pfizer
- 首批 (上市) First Approved (Launched): 2016-11-02 (2017-03)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200680017776.8 (保护期至Expiration 2026-03-30)
    - 专利权人Patent Owner: 惠氏Wyeth
    - 权利要求项Claim(s): 6-7
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL201810299488.0 (保护期至Expiration 2026-03-30)
    - 专利权人Patent Owner: 惠氏Wyeth
    - 权利要求项编号Claim(s): 14-15
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL201210192553.2 (保护期至Expiration 2026-03-30)
    - 专利权人Patent Owner: 惠氏Wyeth
    - 权利要求项Claim(s): 6-10
    - 专利类型Patent Type: 医药用途Medical Use
13价肺炎球菌多糖结合疫苗13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) | 沃安欣®
- 上市许可持有人MAH: 沃森生物Walvax
- 首批 (上市) First Approved (Launched): 2019-12-30 (2020-04)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201810053602.1 (保护期至Expiration 2038-01-19)
  - 专利权人Patent Owner: 沃森生物Walvax
  - 权利要求项Claim(s): 1-3
  - 专利类型Patent Type: 医药用途Medical use

肝炎疫苗Hepatitis Vaccine

冻干甲型肝炎减毒活疫苗 Hepatitis A (Live) Vaccine, Freeze-dried | 海威克
- 上市许可持有人MAH: 长春生物制品研究所
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200810051441.9 (保护期至Expiration 2028-11-17)
    - 专利权人Patent Owner: 长春生物制品研究所有限责任公司
    - 权利要求项Claim(s): 1
    - 专利类型Patent Type: 医药用途Medical use

人乳头瘤病毒疫苗HPV Vaccine

四价人乳头瘤病毒疫苗（酿酒酵母）Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine | 佳达修® GARDASIL®
- 上市许可持有人MAH: 默沙东 Merck
- 首批 (上市) First Approved (Launched): 2017-05-18 (2017-11-04)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL03806347.6 (保护期至Expiration 2023-03-17)
    - 专利权人Patent Owner: 葛兰素史克GlaxoSmithKline (GSK)
    - 权利要求项Claim(s): 21, 23
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL200580019515.5 (保护期至Expiration 2025-06-14)
    - 专利权人Patent Owner: 葛兰素史克GlaxoSmithKline (GSK)
    - 权利要求项Claim(s): 19, 20
    - 专利类型Patent Type: 医药用途Medical Use
九价人乳头瘤病毒疫苗（酿酒酵母）Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine | 佳达修9® GARDASIL 9®
- 上市许可持有人MAH: 默沙东 Merck
- 首批 (上市) First Approved (Launched): 2018-04-28 (2018)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200480007725.8 (保护期至Expiration 2024-03-19)
    - 专利权人Patent Owner: 默沙东Merck
    - 权利要求项Claim(s): 1, 12
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL200480028106.7 (保护期至Expiration 2024-09-24)
    - 专利权人Patent Owner: 默沙东Merck
    - 权利要求项Claim(s): 1
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL03806347.6 (保护期至Expiration 2023-03-17)
    - 专利权人Patent Owner: 默沙东 Merck
    - 权利要求项Claim(s): 21, 23
    - 专利类型Patent Type: 医药用途Medical Use
  - 专利号Patent No.: ZL200580019515.5 (保护期至Expiration 2025-06-14)
    - 专利权人Patent Owner: 默沙东 Merck
    - 权利要求项Claim(s): 19, 20
    - 专利类型Patent Type: 医药用途Medical Use
双价人乳头瘤病毒疫苗（毕赤酵母）Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris) | 沃泽惠®
- 上市许可持有人MAH: 泽润生物Zerun Biotechnology
- 首批 (上市) First Approved (Launched): 2022-03-22 (2022-06-28)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL200710170934.X (保护期至Expiration 2027-11-23)
    - 专利权人Patent Owner: 泽润生物Zerun Biotechnology
    - 权利要求项Claim(s): 1-5
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL200710170935.4 (保护期至Expiration 2027-11-23)
    - 专利权人Patent Owner: 泽润生物Zerun Biotechnology
    - 权利要求项Claim(s): 1-5
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL200710170936.9 (保护期至Expiration 2027-11-23)
    - 专利权人Patent Owner: 泽润生物Zerun Biotechnology
    - 权利要求项Claim(s): 1-5
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence
  - 专利号Patent No.: ZL201410054725.9 (保护期至Expiration 2034-02-18)
    - 专利权人Patent Owner: 泽润生物Zerun Biotechnology
    - 权利要求项Claim(s) No.: 1-5
    - 专利类型Patent Type: 活性成分序列结构Active Ingredient Sequence

疱疹疫苗 Herpes Vaccine

重组带状疱疹疫苗(CHO细胞) Recombinant Zoster Vaccine (CHO Cell) | 欣安立适® SHINGRIX®
- 上市许可持有人MAH: 葛兰素史克GlaxoSmithKline (GSK)
- 首批 (上市) First Approved (Launched): 2019-05-21 (2020-06-28)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201210552767.6 (保护期至Expiration 2026-03-01)
    - 专利权人Patent Owner: 葛兰素史克GlaxoSmithKline (GSK)
    - 权利要求项Claim(s): 1-4
    - 专利类型Patent Type: 医药用途Medical Use

流感疫苗Flu Vaccine

流感病毒裂解疫苗Influenza Vaccine (Split Virion), Inactivated | 适普利尔
- 上市许可持有人MAH: 长春生物Changchun Biotechnology
- 首批 (上市) First Approved (Launched): 2004-09-03 (已上市Launched)
- 专利信息登记详情Registered Patent(s)
  - 专利号Patent No.: ZL201210129270.3 (保护期至Expiration 2032-04-27)
    - 专利权人Patent Owner: 长春生物制品研究所
    - 权利要求项Claim(s): 1
    - 专利类型Patent Type: 医药用途Medical Use

其他 OTHERS

其他OTHERS

黄花蒿花粉变应原 Artemisia Annua Allergens | 畅皓®
上市许可持有人MAH: 我武生物Wolwo Bio-Pharmaceutical
首批 (上市) First Approved (Launched): 2021-01-30 (2021-04-02)
专利信息登记详情Registered Patent(s)

相专利号Patent No.: ZL200910147470.X (保护期至Expiration 2029-06-08)
- 专利权人Patent Owner: 我武生物Wolwo Bio-Pharmaceutical
- 权利要求项编号Claim(s) No.: 39-41
- 专利类型Patent Type: 医药用途Medical Use